ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
FACT II Acquisition Corporation

FACT II Acquisition Corporation (FACT)

9.925
0.005
(0.05%)
Cerrado 25 Enero 3:00PM
9.925
0.00
(0.00%)
Fuera de horario: 3:23PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
9.925
Postura de Compra
9.88
Postura de Venta
15.67
Volume Operado de la Acción
1,920
9.9249 Rango del Día 9.9299
9.85 Rango de 52 semanas 27.01
Precio Anterior
9.92
Precio de Apertura
9.9257
Última hora de negociación
Volumen promedio (3 m)
33,491
Volumen financiero
US$ 19,060
Precio Promedio Ponderado
9.9269

FACT Últimas noticias

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc...

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT...

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for shareholders in connection to the proposed sale of the...

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”) (NasdaqGM: FACT) for possible breaches of fiduciary duty...

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing...

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

SAN FRANCISCO, Jan. 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage cancer biotherapeutics company, today announced the appointment of Hoyoung Huh...

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) and Facet Biotech Corp. (NASDAQ:FACT) today announced the presentation of positive...

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.0150.1513622603439.919.92579.91180979.91918318CS
40.0050.05040322580659.929.92579.881150399.89060785CS
12-17.085-63.254350240727.0127.019.85334919.8907274CS
26-17.085-63.254350240727.0127.019.85146199.8907274CS
52-17.085-63.254350240727.0127.019.8573689.8907274CS
156-17.085-63.254350240727.0127.019.8524439.8907274CS
260-17.085-63.254350240727.0127.019.8517069.8907274CS

FACT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de FACT II Acquisition?
El precio actual de las acciones de FACT II Acquisition es US$ 9.925
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de FACT II Acquisition?
FACT II Acquisition ha negociado en un rango de US$ 9.85 a US$ 27.01 durante el último año

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

FACT Discussion

Ver más
No se encontraron comentarios

Su Consulta Reciente

Delayed Upgrade Clock